Magrolimab plus Azacitidine Versus Azacitidine plus Placebo in Untreated Higher-Risk (HR) Myelodysplastic Syndromes (MDS): The Phase 3, Randomized, ENHANCE Study
Abstract
No abstract.
Paper Details
Title
Magrolimab plus Azacitidine Versus Azacitidine plus Placebo in Untreated Higher-Risk (HR) Myelodysplastic Syndromes (MDS): The Phase 3, Randomized, ENHANCE Study
Published Date
Dec 13, 2021
Volume
21
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History